Abstract: Silencing of a target-genes by small interfering RNA (siRNA) has emerged as a powerful new tool not only for basic research but also with potential therapeutic benefits. This paper demonstrates that optimal delivery strategy is crucial for effective target-gene silencing. Using lipofection, under defined conditions, we were able to markedly down-regulate expression of the selected genes involved in rhabdomyosarcoma metastasis: MET, CXCR4, LIFR and PAX3-FKHR.
Introduction
RNA interference (RNAi) is an evolutionary conserved mechanism employed to protect cells against viral infections and insertion of transposons [1] . RNAi inhibits gene expression by mRNA degradation in a sequencespecific manner upon introduction of double-stranded RNA (dsRNA). First, the long dsRNA is cleaved into 21-nucleotide fragments by an RNase III-like enzyme called Dicer [2] , then the small interfering RNA (siRNA) unwinds into single-stranded RNA and assembles into a multiprotein RNA-induced silencing complex (RISC) [3] . Next, the siRNA guides the entire complex to complementary mRNA molecules. Finally, binding of RISC to target mRNA leads to its cleavage and subsequent degradation [4] or translational repression in a micro RNA (miRNA)-like mechanism [5] . RNAi provides a new, reliable method for functional genomics, pathway analysis and drug target validation experiments. It also seems to be promising therapeutic strategy itself.
In mammalian cells, introduction of dsRNA triggers strong antiviral interferon response, part of the innate immune system targeting viral intermediates [6] . However, it has been reported that shorter siRNA particles can effectively reduce gene expression without inducing an interferon response [4] . The siRNA molecules can be delivered into mammalian cells using a number of different methods, including chemical synthesis [7] , in vitro transcription [8] or vector-based delivery [9] . Chemically synthesized siRNAs are a very convenient research tool. They are produced at a given quantity and purity enabling achievement of highly reproducible results. The synthetic siRNAs need to be transfected into mammalian cells using either lipid-based formulations [10] , electroporation [11] or by linking to peptides [12] .
Regardless of the transfection method, the efficiency of the siRNAs is mostly dependent on the successful rational design of the siRNA sequences. Many companies offer algorithms to design siRNAs. The most efficient silencing is obtained with siRNA duplexes composed of 21-base pairs oligonucleotides with 2-nucleotide long 3'overhangs [13] . As deoxynucleotides in the 3'overhangs are as efficient as ribonucleotides but more nuclease resistant, symmetric 3' TT overhangs are preferentially used. It has been shown that low GC content (30-50%) and lack of inverted repeats positively correlates with siRNA efficiency [14] . It is always recommended to compare the potential target sites to the appropriate genome database and eliminate from consideration any target sequences with more than 16-17 contiguous base pairs of homology to other coding sequences. Despite this, siRNAs still have to be experimentally evaluated for knockdown of individual target gene, because only 1 out of 4-5 designed siRNAs is active [15] .
It is also very important to design the siRNA molecules in a way that homology to non-target genes is minimized and avoided. The design sequence should be checked against the known databases and the sequence with homology to non-targeted genes, particularly in seed region have to be excluded [14] .
Another key to a successful siRNA experiment is careful optimization of the transfection protocol. This paper presents optimization of siRNA delivery into rhabdomyosarcoma cell lines and some guidelines that should be considered during planning RNAi experiments.
Rhabdomyosarcoma (RMS) is relatively uncommon tumor of childhood and adolescence. Based on histopathological and genetical features, two subtypes can be distinguished: embryonal (ERMS) and alweolar (ARMS). ARMS is more aggressive and has a significantly worse outcome then ERMS [16] . Embryonic tumors are characterized by a loss of heterozygosity (LOH) at the 11p15 locus, a region harboring a number of genes implicated in oncogenesis [17] . In contrast to ERMS, most of ARMS carry a characteristic chromosomal translocation resulting in PAX3/FKHR or PAX7/FKHR fusion protein formation [17] .
RMS cells have been found to express the tyrosine kinase receptor MET that plays an important role in cancer development. Hepatocyte Growth Factor/MET signaling regulates multiple cellular processes like cell motility, proliferation and survival, adhesion, extracellular matrix degradation and angiogenesis [18] . In this study, using MET as a principle target, we tested different transfection protocols, siRNA delivery reagents, siRNA concentrations and timing. MET receptor was already a target of RNA interference, however, a lentiviral system was used [19] . After choosing optimal conditions, we also tested siRNA against CXCR4 receptor, LIF receptor (LIFR) and PAX3-FKHR, all of them shown previously to be very important factors contributing to metastatic behavior of RMS cells [17, 20, 21] . CXCR4 has not been targeted previously in a RMS setting. LIFR and PAX3-FKHR fusion protein were already targeted in RMS cells using siRNA [21, 22] .
Experimental Procedures

Cell lines
The rhabdomyosarcoma cell lines used in this study (SMS-CTR and RH30) were maintained in DMEM (Gibco BRL) supplemented with 10% heat-inactivated FBS (Gibco), 100 IU/ml penicillin and 10 mg/ml streptomycin (Gibco). Cells were cultured at 37 o C, 5% CO 2 , 95% humidity. They were split usually twice a week with a medium change.
siRNA preparation
siRNA corresponding to MET receptor gene (siMET#1) and PAX3-FKHR were designed in the lab, as recommended with thymidine dinucleotide overhangs on each strand and chemically synthesized by Eurogentec. The sequence was as follows: MET receptor 5'-AGU CCG AGA UGA AUG UGA Att -3' for sense strand and 5'-UUC ACA UUC AUC UCG GAC Utt -3' for antisense strand; PAX3-FKHR 5'-UGG CCU CUC ACC UCA GAA Utt -3' for sense strand and 5'AUU CUG AGG UGA GAG GCC Att-3' for antisense strand. The annealing for dsRNA was performed according to manufacturer's recommendations.
A second set of siRNA targeting MET was purchased from Ambion and named siMET#2. Also, siRNA targeting CXCR4 and LIFR were purchased from Ambion. The sequences of these siRNAs were not disclosed by the company. FITC labeled non-specific siRNA that was used in optimization experiments came from Qiagen.
Transfection experiments
Transfection of siRNA was conducted with both Lipofectamine 2000 (Invitrogen) and RNAiFect (Qiagen) using either standard or reverse transfection protocol. Standard protocol: 24 hours before transfection SMS-CTR and RH30 cells were trypsinized, counted and seeded at densities of 0.25x10 5 and 0.5x10 5 , respectively, in 0.5 ml DMEM medium supplemented with 10% FBS without antibiotics. On the day of transfection, Lipofectamine 2000 was diluted in 50 ml of serum-free DMEM and combined with siRNA diluted in 50 ml serumfree DMEM. After 20 min of formulation, mixture was added to cell culture. Complexes were also prepared by mixing RNAiFect with siRNA diluted in 100 ml of culture medium containing serum and antibiotics. After 15 min incubation, complexes were applied to the cell culture. Reverse transfection: On the day of transfection SMS-CTR and RH30 cells were trypsynized and counted. 0.5x10 5 SMS-CTR cells and 1x10 5 RH30 cells were suspended in 0.5 ml and combined with complexes as described earlier.
Control experiments were also performed in the same way as described above with the exception that delivery agents were not used.
Viability
Cell viability was determined with the trypan blue (TB) exclusion method (0.4% solution, Sigma Chemicals). Cells treated with siRNA and agents were mixed with TB. Immediately following this live and dead cells were scored under light microscopy.
RNA Extraction and Reverse Transcription
Total RNA was extracted using RNeasy Mini Kit (Qiagen) followed by DNAse treatment (Promega). The reverse polymerase transcription was performed using MMLV reverse transcriptase (Invitrogen) according to manufacturer's protocol.
Quantitative Real Time PCR Analysis
MET expression was determined by quantitative real time PCR analysis on the ABI PRISM 7300 Sequence Detection System (Applied Biosystems, Foster City, CA) using a commercially available primers-probe sets for MET, CXCR4 and LIFR. The mRNA expression level for all samples was normalized to the housekeeping gene GAPDH.
Chemotaxis assay
The directional movement of cells toward the HGF gradient after treatment with MET siRNA was evaluated using modified Boyden's chamber with an 8-mm pore polycarbonate membrane inserts (Costar Transwell; Costar-Corning). Cells detached with 0.25% trypsin were washed and subsequently seeded into the upper chamber of an insert at a density of 2.5x10 4 in 100 µl. The lower chamber was filled with pre-warmed medium containing HGF at 10 ng/ml concentration. DMEM containing 0.5% BSA was used as a negative control. After 24 hours, the inserts were removed from the transwell and cells were fixed with methanol. Cells that did not migrate were scraped off with cotton wool from the upper membrane and cells that had migrated to the lower side of the membrane were stained with Wright solution and counted under high-power field (HPF) microscopy. Five HPF were counted each time and the mean number of cells per HPF was calculated.
Western blot
Western blots were performed on extracts prepared from cells treated with MET siRNA. Briefly, RMS cells were lysed (for 10 minutes) on ice in M-Per lysing buffer (Pierce) containing protease and phosphatase inhibitors (Sigma). Subsequently, the extracted proteins were separated on a 10% sodium dodecyl sulfatepolyacrylamide electrophoresis gel (SDS-PAGE) and the fractionated proteins were transferred onto a PVDF membrane (BioRad). Total level of MET protein was assessed using primary rabbit polyclonal antibodies for MET (Santa Cruz Biotech) and subsequently detecting them with horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary antibody (Santa Cruz Biotech). The membranes were developed with an enhanced chemiluminescence (ECL) reagent (Amersham Life Sciences) and subsequently exposed to HyperFilm (Amersham Life Sciences). Equal loading in the lanes was evaluated by probing with an anti-b-actin antibody (Santa Cruz Biotech).
Flow cytometry
CXCR4 expression was analyzed using anti-CXCR4 mAb -clone 12G5 (Pharmingen). Briefly, 20 ml of CXCR4 mAb was added to 1x10 6 cells suspended in 80 µl of staining buffer (PBS, 2% FBS). Next, the cells were incubated in the dark for 30 min at 4 o C. After incubation cells were washed twice in PBS. Stained cells were washed and collected using FACS Canto cytometer (Becton Dickinson; USA) and analyzed with FACS Diva software (Becton Dickinson; USA).
Statistics
All results are presented as mean value ± SD. Statistical analysis of the data was performed using the Student t-test, where p <0.05 was considered significant.
Results
Choosing the optimal transfection reagent
In this study we tested siRNA delivery efficiency facilitated by Lipofectamine 2000 and RNAiFect. In first set of experiments, FITC-labeled non-specific siRNA was used. RMS cells were transfected with siRNA and delivery efficiency was checked by fluorescence microscopy and FACS analysis after 6 hours post transfection (Figure 1 ). Our data revealed that Lipofectamine 2000 was more efficient in siRNA delivery to RMS cells ( Figure 1A) . Importantly, siRNA was also distributed more homogeneously in cells transfected with Lipofectamine 2000 in comparison to RNAiFect ( Figure 1B ). This is an important observation because siRNA conglomerates could be toxic to cells and decrease effective target-gene inhibition. For this reason, we chose Lipofectamine 2000 as an optimal agent for siRNA delivery into RMS cells. Transfecting cells without any siRNA carriers yielded negative results ( Figure 1C ) suggesting the lack of permissiveness of rhabdomyosarcoma cells for native RNA molecules.
At this point we also tested the influence of the siRNA carriers on cell viability. Cells were incubated with agents for 24 hours and exclusion of trypan blue was examined. We did not observe any significant changes in cell viability with either agent (data not shown).
Choosing the optimal transfection conditions
Reverse transfection, a variation of standard transfection protocol, involves mixing siRNAs, transfection reagent and cells prior to plating the cells. We tested whether this faster and simpler transfection procedure could be applied to RMS cells. Using the FITC-labeled siRNA, we compared both protocols and found no difference in transfection efficiency ( Figure 2) . Next, we performed optimization of Lipofectamine 2000 concentration. Three doses of the agent (2, 4 and 6 ml) were tested and again the FITC-labeled siRNA was used as readout. The lowest, non-toxic concentration of Lipofectamine 2000, which gave the best transfection efficiency, was estimated at 4 ml (Figure 3 ). The goal of our experiments was to knockdown MET receptor expression. Thus, we tested different doses of Lipofectamine 2000 for MET siRNA delivery. By using two different siRNAs complexed with various doses of Lipofectamine 2000, we were able to significantly decrease MET level ( Figure 4A ). Based on obtained data, we decided to use 4 ml of reagent in further studies.
RMS cells were incubated for 4 hours with 1 mg FITC-siRNA and Lipofectamine 2000 (A), RNAiFect (both at 6 ml) (B), or without agent (C) and subsequently analyzed. Left panel -RMS cells under light microscope; right panel -the same cells under fluorescent microscope. Labeling in the presence of Lipo
High concentration of siRNA may lead to undesirable side-effects, thus we tested for the lowest effective concentration of siRNA. qRT-PCR analysis of RMS cells transfected with siRNA ranging from 0.01 to 1 mg showed that we were able to achieve satisfactory results with doses as low as 0.01 mg per transfection ( Figure 4B ). With 0.1 mg siRNA, we obtained a silencing effect that was 2-fold greater (but not statistically significant, p=0.0891). Subsequent experiments were done with 0.1 mg concentration of siMET#1 and siMET#2.
Next, we analyzed the duration of silencing effects and found that knockdown of MET persists until 96 hours after transfection ( Figure 4C ). According to our observation, next experiments were performed within 72 hours after transfection.
Functional analysis of target gene downregulation
Under optimal transfection conditions, a reduction of MET expression in SMS-CTR and RH30 cell lines was achieved with siMET#1 by 87% (p<0.0016) and 88% (p<0.0002), respectively. With siMET#2, 79% inhibition of MET mRNA for SMS-CTR (p<0.0028) and 73% for RH30 (p<0.0004) was achieved ( Figure 5A ). We next investigated whether a reduction in mRNA was reflected at the protein level ( Figure 5 ). It appeared that MET receptor expression was almost undetectable in SMS-CTR cell line after treatment with both siMET#1 and siMET#2. In RH30 cell lines, MET protein expression was considerably lower but detectable with tested siRNAs (Figure 5B ). Downregulation of MET expression, followed by reduction in MET protein level resulted in about 90% inhibition of chemotaxis of both SMS-CTR and RH30 cells (p<<0.001), toward the HGF gradient ( Figure 5C ).
With any experimental procedure, having proper controls is essential. The first validation step of our results was the use of two independent siRNAs targeting MET (siMET#1 and siMET#2). We found similar results with both siRNAs at mRNA and protein level ( Figure 5A and 5B). Secondly, we tested the influence of other siRNAs (siPAX3 and siFKHR) on MET expression. We did not find any effects on the mRNA or protein level of MET (data not shown).
Using optimized transfection conditions we tested siRNAs against CXCR4 and LIF receptors. RMS cells were reverse transfected with 0.1 mg siRNA and 4 ml Lipofectamine 2000. The level of target-gene inhibition was evaluated at 48, 72 and 96 hours. We observed significant downregulation of CXCR4 at 48 (65%, p=0.040) and 72 hours (40%, p=0.0036) ( Figure 6A ). In the case of LIFR, we observed complete inhibition of mRNA expression after 48 hours. At 72 hours posttransfection, mRNA for LIFR was still suppressed, but the change was insignificant (p=0.1421) ( Figure 6B ). With both siRNAs we observed a slow return to baseline level starting after 72 hours post-transfection.
We also tested the siRNA against fusion protein PAX3-FKHR. Downregulation of mRNA expression for the protein was observed after 72 hours, and less so after 96 hours ( Figure 7A ). Since PAX3-FKHR was shown to drive the expression of CXCR4 [20, 23] we tested if inhibition of PAX3-FKHR had any influence on CXCR4 expression. We found that CXCR4 expression correlates to some extent with the expression of the fusion gene. Surface expression of CXCR4 was downregulated from 32.7% of control cells to 21.6% in siPAX3-FKHR treated cells ( Figure 7B ). 
Discussion
The goal of siRNA transfection optimization is to determine conditions that provide maximum gene knockdown while maintaining an acceptable level of viability of target cells. Achievement of the highest transfection efficiency involves several parameters such as transfection method, duration of transfection process, siRNA quality and purity, type of target cells and cell culture conditions.
Chemical transfection (e.g. based on lipid-or aminebased reagents) is typically used for siRNA delivery in immortalized cell lines. In such formulations, cationic lipids bind to oligoribonucleotides through anioncation and hydrophobic interactions. The efficiency of siRNA uptake is dependent upon the cell type and the phospholipid composition. However, since high concentrations of cationic lipids may be toxic to the target cells, their application has to be optimized for each type of target cells [24] . There is a great choice of commercially available reagents with varying levels of effectiveness depending on cell type. Some companies offer agents dedicated to particular cell types. However, these reagents tend to be inefficient for siRNA delivery to most primary cell types and cells grown in suspension. Such difficult-to-transfect cells can be loaded with exogenous siRNAs with electroporation. Electroporation involves applying an electric field pulse to induce the formation of microscopic pores in the cell membrane which allow molecules to traverse the membrane [11] .
With RMS stable, adherent cell lines we did not face any problems with chemical transfection, but found different effectiveness depending on the reagent type. The optimal transfection agent/siRNA ratio should be established to provide maximum transfection efficiency. We found that RMS cell lines can be successfully transfected with siRNA amounts as low as 0.1 mg when accompanied by 4 ml of Lipofectamine 2000.
The transfection procedure itself is also a critical factor. The standard transfection procedure requires preplating cells 24 hours prior to transfection. An alternative transfection procedure, termed reverse transfection, involves simultaneously plating and transfecting cells, similar to procedures used for cells in suspension. This method offers transfection efficiency comparable to standard method but shortens the procedure [25] . In our experiments, we have shown the utility of using 
RH30 cells were exposed to siPAX3-FKHR for 72 and 96 hours (A). Downregulation of PAX3-FKHR mRNA was paralleled by decreased surface expression of CXCR4 (B). Representative experiment out of two performed is shown.
reverse transfection in siRNA delivery into RMS cells, obtaining high efficiency of the process within one-day. Moreover, the standard procedure allows highly efficient transfection of only a limited number of cells, while reverse transfection overcomes this inconvenience [26] . Using a reverse transfection protocol that has not been used previously for RMS cells, we were able to knockdown MET expression in twice as many RMS cells by comparison to the standard protocol. This is particularly important if transfected cells are to be used in assays required by large number of cells such as Western blot or kinase assays.
In this paper we demonstrated that careful optimization of the transfection procedure itself allows specific 80% downregulation of MET receptor in RMS cell lines, without affecting cell viability. Reduction of MET expression results in strong inhibition of directional movement towards a HGF gradient, suggesting functional changes in RMS cells. Our optimized procedure was also efficient with siRNA targeting CXCR4, LIFR and PAX3-FKHR suggesting that optimal transfection conditions can be used for different types of siRNA. Moreover, in addition to a previously published paper showing that downregulation of PAX3-FKHR expression negatively correlates with expression of MET receptor, we have shown that downregulation of PAX3-FKHR also has a negative impact on the expression of CXCR4. Since both receptors have been shown to play a very important role in pathogenesis of RMS [20, 27] , blocking of PAX3-FKHR could have simultaneous impacts on their function in RMS progression and metastasis.
